OvaScience (OVAS) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results
March 15, 2018 4:01 PM EDTInitial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies to Optimize Proposed Phase 1b/2a Clinical Trial
Appointed James Lillie, Ph.D. as Chief Scientific Officer to Lead Advancement of OvaTure Program
Conference Call Today at 4:30 p.m. ET
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a company focused on the discovery and development of new treatment options for women and families struggling with infertility, today reported financial results and provided a business... More
